DEXMETHYLPHENIDATE HYDROCHLORIDE

Post-LOE

dexmethylphenidate hydrochloride

PharmaIN

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Sep 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DEXMETHYLPHENIDATE HYDROCHLORIDE (dexmethylphenidate hydrochloride) by PharmaIN is stimulant. Approved for attention deficit hyperactivity disorder (adhd) [see )], attention deficit hyperactivity disorder (adhd) ( ). First approved in 2020.

Drug data last refreshed 20h ago

Mechanism of Action

stimulant. The mode of therapeutic action in ADHD is not known.

Indications (1)

Attention Deficit Hyperactivity Disorder (ADHD) ( )

Clinical Trials (2)

NCT00829673Phase 1Completed

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

Started Jun 2004

24 enrolled

Healthy

NCT00829712Phase 1Completed

Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions

Started Jun 2004

24 enrolled

Healthy

Company

Worked on DEXMETHYLPHENIDATE HYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.